PharmaTher (PHRRF) News Today $0.36 -0.03 (-7.69%) As of 08/8/2025 01:52 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort InterestBuy This Stock PHRRF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period PharmaTher Holdings Ltd. (PHRM.CN) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comPharmaTher Sets Path for Ketamine Commercialization with FDA Approval GoalJuly 2, 2025 | tipranks.comPharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for KetamineJuly 2, 2025 | globenewswire.comPharmaTher Holdings Ltd. (PHRRF) - Yahoo FinanceJune 26, 2025 | au.finance.yahoo.com2025-06-24 | PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a ... - StockhouseJune 26, 2025 | stockhouse.comPharmaTher Secures U.S. Patent for Ketamine in ALS, Strengthening Market PositionJune 24, 2025 | tipranks.comPharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar MarketJune 24, 2025 | globenewswire.comPharmaTher Applauds FDA's New Commissioner's National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security ApplicationsJune 18, 2025 | globenewswire.comPharmaTher’s Ketamine Drug Review Extended by FDAMay 16, 2025 | tipranks.comPharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025May 16, 2025 | globenewswire.comPharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and CommercializationMay 14, 2025 | globenewswire.comPharmaTher Receives FDA Approval Goal Date for KetamineMarch 11, 2025 | tipranks.comPharmaTher Receives US FDA Approval Goal Date for KetamineMarch 11, 2025 | financialpost.comFPharmaTher Receives US FDA Approval Goal Date for KetamineMarch 11, 2025 | globenewswire.comPharmaTher Resubmits FDA Application for Ketamine, Aiming for Q2-2025 ApprovalMarch 3, 2025 | tipranks.comPharmaTher Holdings Ltd (PHRRF)February 22, 2025 | nasdaq.comPharmaTher Holdings Ltd.: PharmaTher Provides Update on FDA New Drug Application for KetamineFebruary 12, 2025 | finanznachrichten.dePharmaTher expects to submit minor amendment to CRL by end of FebruaryFebruary 12, 2025 | markets.businessinsider.comPharmaTher Advances Towards FDA Approval for Ketamine with Resubmission PlanFebruary 12, 2025 | tipranks.comPharmaTher Provides Update on FDA New Drug Application for KetamineFebruary 12, 2025 | globenewswire.comPharmaTher CEO Issues Letter to ShareholdersJanuary 6, 2025 | markets.businessinsider.comPharmaTher Announces Grant of Stock OptionsJanuary 3, 2025 | globenewswire.comPharmaTher Holdings Ltd.: PharmaTher Announces Update on FDA New Drug Application for KetamineNovember 19, 2024 | finanznachrichten.dePharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug ApplicationNovember 13, 2024 | globenewswire.comPharmaTher receives CRL from FDA for ketamine ANDAOctober 24, 2024 | markets.businessinsider.comPharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug ApplicationOctober 24, 2024 | markets.businessinsider.comBiotech Stocks Facing FDA Decision In October 2024September 30, 2024 | markets.businessinsider.comPharmaTher Announces Update on FDA New Drug Application for KetamineSeptember 4, 2024 | globenewswire.comPharmaDrug’s Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious DiseasesAugust 28, 2024 | msn.comPharmaDrug’s Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) ProteinsAugust 21, 2024 | msn.comPharmaTher's Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) ProteinsAugust 21, 2024 | globenewswire.comPharmaDrug’s Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated CepharanthineAugust 20, 2024 | msn.comPharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)August 20, 2024 | markets.businessinsider.comPharmaTher's Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)August 19, 2024 | globenewswire.comPharmaTher's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated CepharanthineMay 17, 2024 | stockhouse.comPharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated CepharanthineMay 15, 2024 | finance.yahoo.comPharmaTher Holdings Ltd.: PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for KetamineMay 11, 2024 | finanznachrichten.dePharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for KetamineMay 10, 2024 | globenewswire.comPharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated CepharanthineMay 1, 2024 | finance.yahoo.comPharmaTher's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated CepharanthineMay 1, 2024 | globenewswire.comPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineApril 18, 2024 | globenewswire.comPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineApril 16, 2024 | globenewswire.comPharmaTher Holdings Stock (OTC:PHRRF), Short Interest ReportFebruary 23, 2024 | benzinga.comPharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in AustraliaFebruary 21, 2024 | finance.yahoo.comPharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in AustraliaFebruary 21, 2024 | globenewswire.comPharmaTher Holdings Ltd.: PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineFebruary 12, 2024 | finanznachrichten.dePharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineFebruary 12, 2024 | finance.yahoo.comPharmaTher Holdings Stock (OTC:PHRRF) Dividends: History, Yield and DatesJanuary 16, 2024 | benzinga.comPharmaTher Holdings Ltd.: PharmaTher Provides Update for Expected FDA Approval of KetamineJanuary 10, 2024 | finanznachrichten.dePharmaTher expects FDA to decide on ketamine approval by April 29January 10, 2024 | msn.com Get PharmaTher News Delivered to You Automatically Sign up to receive the latest news and ratings for PHRRF and its competitors with MarketBeat's FREE daily newsletter. Email Address PHRRF Media Mentions By Week PHRRF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHRRF News Sentiment▼0.000.50▲Average Medical News Sentiment PHRRF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHRRF Articles This Week▼00▲PHRRF Articles Average Week Get PharmaTher News Delivered to You Automatically Sign up to receive the latest news and ratings for PHRRF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 60 Degrees Pharmaceuticals News Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Ascentage Pharma Group International News Ascletis Pharma News Avacta Group News Awakn Life Sciences News BerGenBio ASA News BriaCell Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTC:PHRRF) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaTher Holdings Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaTher With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHRRF Stock Alerts